ACE-083: dosing from clinical trials
> Updated:
Calculate the ACE-083 dose
Enter your dose and diluent volume for ACE-083 — the calculator will do the rest.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Starting cohort (IM, every 3 weeks) | 150 mg per muscle | Starting dose |
| Escalation (IM, every 3 weeks) | 200 mg per muscle | Increase if needed |
| Main regimen (IM, every 3 weeks) | 240 mg per muscle | Maximum in this schedule |
Practical dosing and effect details
In a study by Statland and colleagues (Muscle & Nerve, 2022) in patients with facioscapulohumeral muscular dystrophy, the ACE-083 dose was escalated stepwise: 150, then 200, then 240 mg per muscle, injected every three weeks for up to 5 doses (about 3 months). At the 200-240 mg doses, total muscle volume (TMV) rose more than 15% from baseline on MRI. In the second part of the study, participants received a fixed 240 mg per muscle dose bilaterally every three weeks for 27 weeks (9 doses); the increase in contractile muscle volume (CMV) versus placebo was statistically significant, though that did not always translate into a clinically noticeable gain in strength or function. The schedule on this page (150, 200, 240 mg, every 3 weeks intramuscularly into the target muscle) reproduces that same studied escalation. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 1 mg vial.ACE-0831 mg+ 2 mlDiluent
- 2Get the concentrationExample: 1 mg in 2 ml =ACE-0830.5 mg/ml(500 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.25 mg dose:0.25 mg = 0.5 ml= 50 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
ACE-083: reference regimens
ACE-083 is a locally acting follistatin-based ligand trap that was injected intramuscularly directly into a target muscle (tibialis anterior or biceps brachii).
ACE-083 dosing in the clinical trials is always tied to a specific muscle rather than body weight: the same milligram dose is injected into one muscle regardless of the participant's weight.
More scientific background in the ACE-083 monograph
Notes and safety
- • ACE-083 is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
ACE-083